Back to the full story3 sources · Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk◆ Analytics
Lilly's Mounjaro, Zepbound sales surge, widening lead over Novo Nordisk
Deterministic text analytics computed across all 3 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
billionlillyzepboundmounjarosalesestimatessurgequarterlyoutlookrevenue
Top phrases
eli lillysales surgetops quarterly estimates raises outlookeasily tops quarterly estimates raiseslilly easily tops quarterly estimatesestimates raises outlook as zepboundquarterly estimates raises outlookzepbound and mounjaro sales surgeoutlook as zepbound and mounjaroeasily tops quarterly estimates
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Zepbound · 3 sources
- Eli Lilly · 2 sources
- Mounjaro · 2 sources
Unique to one source
- Lilly's Mounjaro · Yahoo Finance
- Novo Nordisk · Yahoo Finance
- Wall Street · Quartz
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "Eli Lilly now expects 2026 revenue to come in between $85 billion and $87 billion, up from previous guidance of $82 billion to $85 billion." · CNBC
- "Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates Mounjaro revenue jumped 91% to $9.9 billion and Zepbound brought in $4.9 billion as the drugmaker beat Wall Street estimates" · Quartz